Przybylski K G, Rybak M J, Martin P R, Weingarten C M, Zaran F K, Stevenson J G, Levine D P
Department of Pharmacy Services, Detroit Receiving Hospital, Michigan 48201, USA.
Pharmacotherapy. 1997 Mar-Apr;17(2):271-6.
A prospective program to convert patients from parenteral to oral antibiotics was evaluated over 12 months to determine its pharmacoeconomic impact on antibiotic acquisition and length of hospital stay. Physicians of patients meeting predetermined clinical criteria for mild and moderate infections were contacted to discuss potential oral alternative therapy. Clinical end points and economic data were followed in 242 patients (200 converted and 42 not converted but meeting criteria). No significant differences were noted between the groups with regard to demographic data, infection diagnosis, clinical outcome, or adverse effects. The average number of days of therapy for patients converted was 1.53 days shorter than that of patients who were not converted to oral therapy (p < 0.003). Cost savings for drug acquisition and length of stay were $15,149.24 and $161,071.88, respectively. The intervention program appeared to provide a cost-effective conversion from parenteral to oral antimicrobial administration without compromising patient care. It is anticipated that expansion of the program to include additional antibiotics will result in even greater cost savings for the institution.
一项将患者从肠外抗生素转换为口服抗生素的前瞻性计划在12个月内进行了评估，以确定其对抗生素采购和住院时间的药物经济学影响。联系了符合轻度和中度感染预定临床标准的患者的医生，讨论潜在的口服替代疗法。对242名患者（200名转换患者和42名未转换但符合标准的患者）进行了临床终点和经济数据跟踪。两组在人口统计学数据、感染诊断、临床结果或不良反应方面没有显著差异。转换患者的平均治疗天数比未转换为口服治疗的患者短1.53天（p<0.003）。药物采购和住院时间的成本节省分别为15,149.24美元和161,071.88美元。该干预计划似乎提供了一种从肠外抗菌给药到口服抗菌给药的具有成本效益的转换，而不会影响患者护理。预计将该计划扩展到包括更多抗生素将为该机构带来更大的成本节省。
